Literature DB >> 26325437

Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.

Yundai Chen1, Wei Dong2, Zheng Wan3, Zhanquan Li4, Hongliang Cong5, Tao Hong6, Tong Yin2.   

Abstract

Entities:  

Keywords:  Acute coronary syndromes; Antiplatelet; Clopidogrel; Ticagrelor

Mesh：

Substances：

Year:  2015        PMID： 26325437     DOI： 10.1016/j.ijcard.2015.06.030

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  5 in total

1.  Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate.

Authors:  Hai-Bo Wu; Huan-Ping Tian; Xue-Chao Wang; Shi-Ru Bai; Xin-Ning Li; Li-Na Zhang; Rong-Pin Du
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

2.  Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

Authors:  Heyang Wang; Jing Qi; Yi Li; Yunbiao Tang; Chao Li; Jing Li; Yaling Han
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

Review 3.  Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome.

Authors:  Korakoth Towashiraporn; Rungroj Krittayaphong
Journal:  Int J Gen Med       Date:  2022-03-03

4.  Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.

Authors:  Yunxian Chen; Shaowen Tu; Zhixin Chen; Jue Xia; Baofeng Chen; Jinfeng Chen; Jiarong Liang; Xiangyang Liu; Liangqiu Tang
Journal:  J Interv Cardiol       Date:  2022-07-31       Impact factor: 1.776

5.  Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.

Authors:  Hongwu Chen; Xiaofan Yu; Xiangyong Kong; Longwei Li; Jiawei Wu; Likun Ma
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.